<DOC>
	<DOCNO>NCT02130310</DOCNO>
	<brief_summary>The primary objective evaluate clinical benefit CureXcell® adjunct Standard Care treatment Chronic Venous Leg Ulcers . CureXcell® cell base therapy , contain activate homologous white blood cell prepare donate healthy whole blood . A total 252 patient randomize receive either CureXcell® Placebo .</brief_summary>
	<brief_title>Evaluation CureXcell® Treating Chronic Venous Leg Ulcers</brief_title>
	<detailed_description />
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Leg Ulcer</mesh_term>
	<mesh_term>Varicose Ulcer</mesh_term>
	<criteria>Ankle Brachial Pressure Index ( ABI ) ≥ 0.80 Venous insufficiency confirm duplex Doppler ultrasound Presence venous leg ulcer , unresponsive Standard Care treatment least 4 week ≥ 1 cm2 ≤ 17.1 cm2 screening ; ≥ 1 cm2 ≤ 12cm2 Baseline Visit Target Ulcer decrease &gt; 30 % size Screening Baseline Documented history osteomyelitis Target Ulcer location within 6 month precede Baseline Visit . Patients unable tolerate multilayer compression therapy . Ulcer , opinion Investigator suspicious cancer . Any malignancy within past 5 year , exclude successfully treat basal cell carcinoma squamous cell carcinoma without evidence metastasis . History radiation Target Ulcer site previous 12 month prior Baseline Visit . Patients clinically significant claudication Current sepsis Patients known history significantly compromise immunity reason include radiation therapy , chemotherapy HIV</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>Chronic ulcer</keyword>
	<keyword>Venous ulcer</keyword>
</DOC>